IN2014CN04071A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04071A
IN2014CN04071A IN4071CHN2014A IN2014CN04071A IN 2014CN04071 A IN2014CN04071 A IN 2014CN04071A IN 4071CHN2014 A IN4071CHN2014 A IN 4071CHN2014A IN 2014CN04071 A IN2014CN04071 A IN 2014CN04071A
Authority
IN
India
Prior art keywords
antigen
tcdb
relates
tcda
difficile
Prior art date
Application number
Other languages
English (en)
Inventor
Maria Scarselli
Mariagrazia Pizza
Rosanna Leuzzi
Maria Arico
Manuele Martinelli
Gillian Douce
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201121149A external-priority patent/GB201121149D0/en
Priority claimed from GBGB1217321.7A external-priority patent/GB201217321D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014CN04071A publication Critical patent/IN2014CN04071A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN4071CHN2014 2011-12-08 2012-12-07 IN2014CN04071A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201121149A GB201121149D0 (en) 2011-12-08 2011-12-08 Clostridium difficile toxin-based vaccine
GBGB1217321.7A GB201217321D0 (en) 2012-09-27 2012-09-27 Vaccine
PCT/IB2012/002955 WO2013084071A2 (fr) 2011-12-08 2012-12-07 Vaccin à base de toxines de clostridium difficile

Publications (1)

Publication Number Publication Date
IN2014CN04071A true IN2014CN04071A (fr) 2015-10-23

Family

ID=47747684

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4071CHN2014 IN2014CN04071A (fr) 2011-12-08 2012-12-07

Country Status (15)

Country Link
US (1) US9694063B2 (fr)
EP (1) EP2788022B1 (fr)
JP (1) JP6084631B2 (fr)
KR (1) KR20140101835A (fr)
CN (1) CN103974718A (fr)
AU (1) AU2012349753A1 (fr)
BR (1) BR112014013876A2 (fr)
CA (1) CA2858519A1 (fr)
ES (1) ES2704069T3 (fr)
IL (1) IL232957A0 (fr)
IN (1) IN2014CN04071A (fr)
MX (1) MX2014006630A (fr)
RU (1) RU2014127714A (fr)
SG (1) SG11201402375VA (fr)
WO (1) WO2013084071A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5917682B2 (ja) 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
CA2882620A1 (fr) 2012-09-19 2014-03-27 Novartis Ag Polypeptides de clostridium difficile utilises comme vaccins
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014197651A1 (fr) * 2013-06-05 2014-12-11 Tufts University Holotoxines recombinantes atoxiques de clostridium difficile au titre d'immunogènes
US10835595B2 (en) 2014-01-06 2020-11-17 The Trustees Of The University Of Pennsylvania PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
PL3160500T3 (pl) * 2014-06-25 2020-02-28 Glaxosmithkline Biologicals S.A. Immunogenna kompozycja clostridium difficile
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
MX2021014097A (es) * 2019-05-21 2022-03-11 Univ California Composiciones de vacunas para clostridium difficile.

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JPH04500203A (ja) 1988-08-25 1992-01-16 ザ　リポソーム　カンパニー，インコーポレイテッド インフルエンザワクチンおよび新規なアジュバント
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (fr) 1989-01-17 1990-07-17 Antonello Pessi Peptides synthetiques et leur utilisation comme porteurs universels pour la preparation de conjugats immunogenes convenant a la mise au point de vaccins synthetiques
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
ATE366312T1 (de) * 1994-10-24 2007-07-15 Ophidian Pharm Inc Impfstoff und antitoxine zur behandlung und vorbeugung von c. difficile krankheiten
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
JPH11509200A (ja) 1995-07-07 1999-08-17 オラバックス インク． 粘膜アジュバントとしてのクロストリジウム・ディフィシール（Ｃｌｏｓｔｒｉｄｉｕｍ Ｄｉｆｆｉｃｉｌｅ）トキシン
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
EP1105153A4 (fr) 1996-08-28 2005-01-19 Ophidian Pharm Inc Vaccin polyvalent contre la neurotoxine du (clostridium botilinum)
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1000155A1 (fr) * 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Fragments immunogenes de toxine a de clostridium difficile
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1279401B1 (fr) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Emulsions du type huile-dans-l'eau contenant des saponines
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
IL137809A0 (en) 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US20020009429A1 (en) * 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
EP1880735A3 (fr) 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccin
JP2002542169A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
CA2409672A1 (fr) * 2000-05-10 2001-11-15 Glycodesign Inc. Conception de modulateurs pour glycosyltransferases
EP2189473A3 (fr) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
AU2002338233A1 (en) * 2001-03-30 2002-10-15 Basf Plant Science Gmbh Glucan chain length domains
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003024481A2 (fr) 2001-09-14 2003-03-27 Cytos Biotechnology Ag Emballage de substances immunnostimulatrices dans des particules de type virus : procede de preparation et utilisation correspondants
WO2004041857A2 (fr) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant de la toxine b de clostridium difficile et methodes d'utilisation
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
PL1766093T3 (pl) 2004-02-06 2011-11-30 Univ Massachusetts Przeciwciała przeciw toksynom Clostridium difficile i ich zastosowania
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
WO2007146139A2 (fr) 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Molécules d'adn optimisées au niveau des codons codant pour les domaines de liaison avec le récepteur des toxines a et b
WO2008014733A1 (fr) 2006-08-02 2008-02-07 Johannes Gutenberg-Universität Mainz Médicament contre les empoisonnements dus à des toxines lct
CA2693958A1 (fr) * 2007-06-14 2008-12-18 Emergent Biosolutions, Inc. Peptides chimiquement modifies presentant une meilleure immunogenicite
WO2008156676A1 (fr) * 2007-06-15 2008-12-24 President And Fellows Of Harvard College Procédés et compositions de détection et de modulation de o-glycosylation
CA2733425A1 (fr) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccins contre clostridium difficile, et procedes d'utilisation
JP5740714B2 (ja) 2009-02-20 2015-06-24 ヘルス プロテクション エージェンシー クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体
CA2772400A1 (fr) * 2009-08-27 2011-03-17 Synaptic Research, Llc Nouveau systeme d'administration de proteine pour generer des cellules souches pluripotentes induites (ips) ou des cellules specifiques de tissu
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
US20120282274A1 (en) 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
CA2782406A1 (fr) * 2009-12-02 2011-06-09 Tufts University Holotoxines recombinantes atoxiques de clostridium difficile au titre d'immunogenes
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
EP2553102B1 (fr) 2010-03-30 2015-12-09 Pfenex Inc. Expression de protéines de toxines recombinantes en forte quantité
JP5965389B2 (ja) * 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
BR112014004896B1 (pt) 2010-09-03 2023-02-14 Valneva Usa, Inc. Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo
US8431361B2 (en) 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
US8906635B2 (en) 2011-02-28 2014-12-09 Northshore University Healthsystem Methods of diagnosing Clostridium difficile infection
JP5917682B2 (ja) 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
ES2615737T3 (es) 2011-05-27 2017-06-08 Glaxosmithkline Biologicals S.A. Composición inmunogénica
AR087716A1 (es) * 2011-08-31 2014-04-09 Valent Biosciences Corp Composiciones reguladoras del crecimiento de plantas, metodos de preparacion y usos de las mismas
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Also Published As

Publication number Publication date
ES2704069T3 (es) 2019-03-14
MX2014006630A (es) 2014-07-09
CA2858519A1 (fr) 2013-06-13
SG11201402375VA (en) 2014-10-30
IL232957A0 (en) 2014-07-31
AU2012349753A1 (en) 2014-06-19
WO2013084071A3 (fr) 2013-11-07
US9694063B2 (en) 2017-07-04
RU2014127714A (ru) 2016-01-27
EP2788022A2 (fr) 2014-10-15
KR20140101835A (ko) 2014-08-20
CN103974718A (zh) 2014-08-06
US20150132333A1 (en) 2015-05-14
EP2788022B1 (fr) 2018-10-31
BR112014013876A2 (pt) 2019-09-24
JP6084631B2 (ja) 2017-02-22
WO2013084071A2 (fr) 2013-06-13
JP2015500827A (ja) 2015-01-08

Similar Documents

Publication Publication Date Title
IN2014CN04071A (fr)
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
IL242934B (en) Microbiota restoration therapy (mrt) compounds and methods of manufacture
TN2015000050A1 (en) Methods of treating a tauopathy
NZ715815A (en) High-stability t-cell receptor and preparation method and application thereof
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
MX2014004022A (es) Anticuerpos anti-htra1 y metodos de uso.
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
IN2014DN05885A (fr)
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
WO2012166626A8 (fr) Réactifs et procédés pour traiter une maladie dentaire
AU337887S (en) Allsaw
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
EP4023243A3 (fr) Compositions et procédés pour le traitement de la maladie c liaque
WO2013123046A3 (fr) Matériaux tampons de cathode et dispositifs et procédés associés
PH12015501854A1 (en) Factor ix polypeptide formulations
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
MX2023003000A (es) Formulaciones de liberacion modificada de viloxacina.
IN2015DN00820A (fr)
AU337888S (en) Allsaw